evipedia.ai
← Back

Solubilized Keratin for Health & Longevity

Evidence Review created on 11/02/2026 using AI4L / Opus 5.5

Also known as: Soluble Keratin, Solubilised Keratin, Keratin Hydrolysate, Hydrolyzed Keratin, Feather Keratin Hydrolysate, Cynatine, Cynatine HNS, Cynatine FLX, Kera-Diet, KeraGLO, KerPep, keraGEN-IV

Motivation

Keratin is the tough protein that makes up hair, nails, and the outer layer of skin, and it is also the main protein of sheep wool and poultry feathers. In its natural form the human gut cannot digest it. Solubilized keratin is keratin that manufacturers have broken down, by controlled chemical or enzyme-based processing, into a water-soluble form the body can absorb. It is sold as a dietary supplement, mostly in hair, skin, and nail formulas, and has also been explored as a protein source.

Interest grew because keratin is unusually rich in a sulfur-containing amino acid that the body uses to build its own keratin and its antioxidant defenses. Branded ingredients made from New Zealand wool and from poultry feathers have been tested in small placebo-controlled studies, mainly of hair, nails, and skin.

This review examines what human, animal, and laboratory evidence shows about solubilized keratin for health-focused adults: which benefits are supported and how strongly, what risks and interactions exist, who paid for the research, and how the findings relate to the pursuit of a longer, healthier life.

Benefits - Risks - Protocol - Conclusion

Overviews and commentary that discuss solubilized keratin as an oral supplement or dietary protein in depth.

Only four items qualify because in-depth content on oral keratin is scarce. No substantive keratin content was found on FoundMyFitness (Rhonda Patrick), peterattiamd.com (Peter Attia), hubermanlab.com (Andrew Huberman), chriskresser.com (Chris Kresser), or lifespan.io; their site searches returned only passing mentions of keratin as the protein of hair.

Grokipedia

No Grokipedia article on solubilized keratin or keratin supplementation exists; the general Grokipedia “Keratin” article covers only the protein’s biology and disease roles.

Examine

  • Keratin

    Examine’s keratin page is a short research feed rather than a full monograph; it summarizes the feather keratin hydrolysate skin trial and lists keratin-containing hair formulas, with details behind a paywall.

ConsumerLab

No ConsumerLab article on solubilized keratin exists; keratin appears only in passing elsewhere, such as a ConsumerLab 2021 recall of a biotin–collagen–keratin capsule over a fish allergen in its collagen ingredient.

Systematic Reviews

One systematic review with meta-analysis includes a solubilized keratin product; none evaluates keratin alone.

The principal risk side is unrepresented: no systematic review or meta-analysis has evaluated the safety of solubilized keratin.

Mechanism of Action

Native keratin is held by disulfide bonds (sulfur–sulfur bridges between cysteine units), which make it insoluble and indigestible; solubilization breaks these bonds chemically or enzymatically (Giteru 2023). Products differ:

  • Wool keratin (Cynatine): peptides from proprietary processing of New Zealand sheep wool, per a trial co-authored by a Roxlor employee (Beer 2014).
  • Feather hydrolysate (Kera-Diet, sold as KeraGLO in the US): at least 83.5% free amino acids plus small peptides, made by BCF Life Sciences (Tursi 2025); BCF employees co-authored that trial despite a “no conflicts” declaration.
  • Soluble feather keratin (research product): about 83% digestible, retaining about 87% of its thiol (sulfur) content; processing yields cysteic acid (oxidized cysteine) (Crum 2018); Keraplast, its maker, part-funded that trial.

Proposed actions:

  • Amino acid supply: cysteine and cystine for the body’s keratin; hair cystine content rose 8.6% with a keratin–vitamin formula (Beer 2014).
  • Antioxidant support: in Keraplast-funded rat work, cysteic acid from keratin maintained glutathione (the cell’s main antioxidant) and raised liver taurine (a sulfur compound) (Wolber 2016).
  • Signaling peptides: in mice, in Dong-A Pharm co-authored work, keratin peptides activated β-catenin (a protein that switches on hair-growth genes) (Kim 2026).

The competing view: digested keratin is amino acids, with no evidence it reaches hair as keratin; trial effects may reflect co-ingredients such as biotin. As a food protein it has no half-life, receptor selectivity, or cytochrome P450 (liver drug-metabolizing enzyme) metabolism; plasma amino acids peak about 20 minutes after ingestion in a BCF-sponsored study (Wauquier 2026).

Historical Context & Evolution

Feathers and wool were long treated as waste. Feathers were ground into feather meal for animal feed, where low digestibility limited their value (Crum 2018). Keratin also had biomaterial uses: in New Zealand, keratin wound dressings sped healing of skin-graft donor sites in older patients in a randomized trial (Davidson 2013). In multi-ingredient hair formulas, keratin has appeared as a minor ingredient alongside cystine, yeast, and B vitamins (Sant’Anna Addor 2018).

Health-optimization interest followed processing advances that made keratin digestible while keeping its sulfur. The wool-derived Cynatine ingredient, developed in New Zealand, was tested in three trials funded by its marketer Roxlor and published in 2013–2014, covering skin (Beer 2013), knee osteoarthritis (Beer 2013), and hair and nails (Beer 2014).

Massey University researchers, with product and partial funding from keratin maker Keraplast, then studied soluble feather keratin as a cysteine-rich protein in rats (Wolber 2016) and cyclists (Crum 2018). More recently, a free-amino-acid feather hydrolysate was tested for skin aging (Tursi 2025). What changed over time is the rationale: from replacing lost keratin to supplying amino acids. No independent group has yet replicated any human finding.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: each keratin-alone human finding comes from one or two small manufacturer-linked randomized trials, and the outcomes are cosmetic instrument readings or unreplicated clinical scores.

Medium 🟩 🟩

Nail Hardness and Brittleness ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

In a 90-day randomized controlled trial (RCT, participants assigned by chance to product or placebo) of 99 women, feather keratin hydrolysate alone improved clinician-rated nail hardness (Tursi 2025). A keratin–biotin–zinc formula reduced breakage, but co-ingredients confound it (Beer 2014). In a 60-day RCT of 65 women co-authored by distributor AIDP, wool keratin (keraGEN-IV) alone did not change self-rated nail strength versus placebo (Kelly 2024); its different source and shorter duration may explain the discrepancy. It bears on nail appearance. Net reading: the larger, longer trial favors a modest benefit.

Magnitude: Clinician-rated nail hardness on a 0–10 scale rose 2.1 points with 1,000 mg/day and 1.5 points with 500 mg/day versus 0.2 points with placebo at day 90; the between-group p (probability that a difference this large arises by chance) was <0.001, and no confidence interval (range likely to contain the true effect) was reported (Tursi 2025).

Skin Elasticity, Hydration, and Roughness ⭕️ Not Central to Health & Longevity

In the same 99-woman RCT, feather keratin hydrolysate alone improved skin elasticity, deep skin moisture, roughness, and wrinkle depth versus placebo over 90 days (Tursi 2025). A Roxlor-funded RCT of 50 women taking the keratin–vitamin formula reported similar improvements, but co-ingredients confound it (Beer 2013). Dermal fiber density did not differ significantly from placebo. This outcome bears on skin appearance rather than health or lifespan.

Magnitude: At day 90, skin elasticity rose 7.6% with 1,000 mg/day versus 0.6% with placebo, and skin roughness fell 7.2% versus a 2.0% rise with placebo (between-group differences significant; no confidence interval reported) (Tursi 2025).

Lean Mass Gain During Endurance Training

In a blinded crossover RCT part-funded by keratin maker Keraplast, 15 trained male cyclists took 0.8 g/kg/day of soluble feather keratin or casein (milk protein) for 4 weeks each. Lean mass measured by DEXA (dual-energy X-ray absorptiometry, a low-dose body-composition scan) rose more with keratin, mainly in the legs (Crum 2018). The trial had no unsupplemented arm, casein produced unusually little gain, and the result is unreplicated. Lean mass bears on muscle maintenance with age.

Magnitude: Whole-body lean mass rose 0.88 kg with keratin versus 0.07 kg with casein (p=0.043 for the difference in change over time between the two proteins; no between-group confidence interval reported); leg lean mass rose 0.45 kg versus −0.04 kg (Crum 2018).

Low 🟩

Knee Osteoarthritis Pain ⚠️ Conflicted

In a 50-adult RCT, 500 mg/day wool keratin (Cynatine FLX) eased WOMAC (an osteoarthritis symptom questionnaire) pain and stiffness faster than placebo, but groups did not differ at day 60, which the abstract omits (Beer 2013); a keratin combination pilot reported gains (Oliviero 2020). Net reading: benefit appears transient.

Magnitude: At day 6, WOMAC pain improved 13% with keratin versus 0.73% with placebo, and stiffness 19.4% versus 4.9%; by day 60 neither differed significantly between groups (no confidence interval reported) (Beer 2013).

Hair Shedding and Hair Shaft Quality ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

A keratin–biotin–zinc–B-vitamin formula reduced pull-test hair loss (hairs extracted by a gentle tug) in 50 women (Beer 2014), confounded by co-ingredients. Keratin alone improved hair gloss (Tursi 2025) but reduced pull-test loss only borderline versus placebo (Kelly 2024). It bears on hair appearance. Net reading: keratin’s own benefit is unconfirmed.

Magnitude: Pull-test hair loss was 34.4% lower than placebo at day 90 with the combination formula (p<0.001; no confidence interval reported) (Beer 2014); with keratin alone, pull-test loss fell 43.1% from baseline versus 14.1% with placebo, a borderline between-group difference (Kelly 2024).

Endurance Capacity and Red Blood Cell Measures ⚠️ Conflicted

In rats, a keratin diet raised haemoglobin and haematocrit (red-cell share of blood) by about 5% (Wolber 2016). In 15 trained cyclists, 4 weeks of keratin changed neither these measures, maximal oxygen uptake, nor peak power versus casein (Crum 2018). Net reading: human data show no endurance benefit.

Magnitude: Post-intervention haemoglobin was 148 g/L with keratin versus 150 g/L with casein, and maximal power output showed no treatment effect (p=0.51) (Crum 2018).

Speculative 🟨

Glutathione and Antioxidant Support

Rat data show keratin-derived cysteic acid sustains glutathione (Wolber 2016); post-dose serum protected cultured cells from oxidative stress (Wauquier 2026). A wool-industry co-funded diabetes trial of keratin plus whey found unclear glutathione effects (Peeters 2023).

Blood Lipid Lowering

A feather protein hydrolysate improved blood lipids and liver antioxidant enzymes in mice fed a high-fat diet (Ben Hamad Bouhamed 2019). No human study exists; the basis is animal data only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study has examined genetic modifiers of response. Variants in CBS (cystathionine beta-synthase, an enzyme channeling homocysteine toward cysteine) could theoretically change how much extra cysteine matters, but this is untested.
  • Baseline nutrient status: People with low protein, zinc, or biotin intake may respond more, partly through co-ingredients; trials did not stratify by baseline status. Hair loss from iron deficiency or thyroid disease would not be expected to respond to keratin.
  • Sex: Hair, skin, and nail trials enrolled only women (Tursi 2025), and the lean-mass trial only men (Crum 2018); whether effects differ by sex is unknown.
  • Pre-existing conditions: Benefits were seen in people with brittle nails, damaged hair, or knee osteoarthritis. Women whose nails were already strong had no room to improve and were excluded from that analysis (Beer 2014).
  • Age: Trials enrolled adults aged 18–71; no data exist beyond 71. Older adults with low protein intake might gain more from protein-level doses, but no trial has tested keratin in older adults.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: human safety data come from seven small trials lasting 4–14 weeks that collected adverse events passively, and none attributed a serious adverse event to keratin.

Medium 🟥 🟥

No risk reaches Medium: the only human signals for keratin itself are anecdotal reports and dropouts without excess over placebo, and the one well-documented harm comes from a co-ingredient rather than keratin.

Low 🟥

Gastrointestinal Discomfort and Sulfurous Flatulence ⚠️ Conflicted

At protein-level doses, cyclists anecdotally reported sulfur-smelling flatulence (Crum 2018). In a cosmetic-dose randomized trial, intolerance withdrawals occurred equally with placebo (Beer 2014). Net reading: mild digestive effects are plausible at protein-level doses, with no excess over placebo at cosmetic doses.

Magnitude: Intolerance-related withdrawal occurred in 1 of 25 women on the keratin formula versus 1 of 25 on placebo (Beer 2014); flatulence was reported anecdotally without counts (Crum 2018).

Laboratory Test Interference From Biotin-Containing Formulas

Keratin hair formulas often add biotin, which distorts some immunoassays (lab tests using antibodies), including troponin (a heart-damage marker), as the US Food and Drug Administration (FDA) warns (FDA biotin–troponin page). Evidence is indirect: a co-ingredient, tested at 10 mg/day (Li 2017).

Magnitude: At 10 mg/day biotin, 9 of 23 (39%) biotin-based immunoassays gave false results versus 0 of 14 assays without biotin chemistry (no control group of people) (Li 2017).

Speculative 🟨

Hypersensitivity to Animal-Derived Keratin

Wool- or feather-sourced keratin could trigger allergy in sensitized people. No case has been published; an industry-funded cosmetics panel judged topical keratin ingredients safe (Burnett 2021). Basis is mechanistic only.

Reduced Fat Digestibility

When keratin replaced half of dietary protein in rats, fat digestibility fell (Wolber 2016). No human data exist; basis is animal only.

Contaminants and Processing Residues

Feather and wool raw materials and harsh hydrolysis could leave contaminants or reagent residues; long-term safety studies of newer extraction methods are lacking (Giteru 2023). Basis is mechanistic only.

Risk-Modifying Factors

  • Genetic polymorphisms: Variants in SLC3A1 or SLC7A9 (genes for the kidney’s cystine reabsorption transporter) cause cystinuria (inherited cystine kidney stones), where extra cystine could add stone risk. Variants in ATP7B (a copper-exporting enzyme) cause Wilson’s disease (toxic copper build-up), relevant to copper-containing formulas.
  • Baseline biomarkers: Reduced eGFR (estimated glomerular filtration rate, the kidneys’ filtering capacity) matters for gram-level protein doses under a guideline whose authors gain no revenue from keratin (Ikizler 2020). Pre-existing high zinc or low copper status matters for formulas adding these minerals.
  • Sex: No sex-specific risk data exist. Pregnant and breastfeeding women were excluded from trials, so safety in pregnancy and lactation is unstudied.
  • Pre-existing conditions: Known wool, feather, or poultry protein allergy; chronic kidney disease for protein-level doses; and any condition requiring troponin or thyroid testing while taking biotin-containing formulas.
  • Age: Older adults more often undergo cardiac and thyroid blood tests and take quinolone antibiotics, so biotin and zinc co-ingredients matter more with age; trials included no one over 71.

Key Interactions & Contraindications

Documented interactions:

  • Quinolone antibiotics (ciprofloxacin, levofloxacin) with zinc-containing keratin formulas: a multivitamin with zinc lowered total ciprofloxacin exposure (area under the concentration curve) from 14.5 to 11.3 µg·h/mL (Polk 1989), risking weaker antibiotic effect. Mitigation: separating doses (timing untested).
  • Biotin-based laboratory immunoassays (troponin, thyroid hormones) with biotin-containing keratin formulas: falsely low troponin (FDA biotin–troponin page) and falsely high or low thyroid-hormone results at 10 mg/day biotin (Li 2017). Mitigation: pausing the formula before blood draws and informing the laboratory.
  • Over-the-counter acid reducers (omeprazole, esomeprazole) with zinc-containing keratin formulas: in 14 healthy volunteers, 7 days of omeprazole 60 mg/day cut absorption of oral zinc from 245 to 141 mg/dL/h (Ozutemiz 2002), risking reduced zinc uptake. Mitigation: zinc-free products for long-term users.
  • Levodopa (a Parkinson’s disease drug; Sinemet, Rytary) with protein-level keratin doses: in Parkinson’s patients, oral large neutral amino acids and high-protein meals reversed levodopa’s effect by competing for brain transport (Nutt 1984); keratin itself untested. Mitigation: taking keratin apart from levodopa doses.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Other cysteine donors (N-acetylcysteine, glutathione, L-cystine supplements): additive sulfur amino acid load, inferred from shared cysteine content; consequence possibly more flatulence. Mitigation: counting total intake.
  • Over-the-counter biotin, zinc, or copper supplements and multivitamins: additive mineral and biotin intake, inferred from overlapping ingredients; consequences include greater lab interference and zinc-induced copper imbalance. Mitigation: totaling all sources.
  • Copper-chelating drugs (medicines that bind and remove copper; penicillamine, trientine) with copper-containing formulas: added copper may counteract chelation therapy, inferred from opposing effects on copper balance. Mitigation: choosing copper-free keratin products.
  • Collagen peptides, biotin, silicon (orthosilicic acid): additive intended effects on hair, skin, and nails, inferred from overlapping targets; no harmful consequence identified. Mitigation: none needed beyond biotin timing before tests.

Populations who should avoid Solubilized Keratin:

  • Wilson’s disease (inherited toxic copper build-up) or other inborn errors of copper metabolism: the product label advises against daily use of copper-containing formulas (Life Extension label).
  • Chronic kidney disease stages 3–5 not on dialysis, for protein-level doses: a National Kidney Foundation guideline, whose authors gain no revenue from keratin, recommends 0.55–0.6 g/kg/day total protein (Ikizler 2020), which gram-level keratin can exceed.
  • Known allergy to wool, feather, or poultry protein: inferred from the animal origin of the protein; no human data.
  • Cystinuria (inherited cystine kidney stones): inferred from the high cystine content of keratin; no human data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Pausing biotin-containing formulas before blood tests: biotin causes falsely low troponin (FDA biotin–troponin page) and falsely high or low hormone results (Li 2017); stopping at least 3 days before testing and informing the laboratory prevents this.
  • Keratin-only products when biotin is unwanted: keratin-alone ingredients avoid biotin-related laboratory interference and allow keratin’s own effect to be judged.
  • Separating zinc-containing formulas from quinolone antibiotics: taking zinc-containing products together with ciprofloxacin lowered its absorption (Polk 1989); taking ciprofloxacin at least 2 hours before or 6 hours after them is common practice to avoid this.
  • Taking with food and building up gram doses: starting protein-level intake at about half the target for one week limits digestive discomfort and sulfurous flatulence.
  • Kidney function check before protein-level doses: an eGFR below 60 mL/min/1.73 m² marks the point where gram-level keratin could push protein intake above the chronic kidney disease guideline, whose authors gain no revenue from keratin (Ikizler 2020).
  • Copper-free formulas in copper disorders: the label advises people with Wilson’s disease against daily use of copper-containing products, preventing copper accumulation (Life Extension label).
  • Stopping at signs of allergy: hives, swelling, or wheeze may signal hypersensitivity to animal-derived protein and are a common reason to discontinue.
  • Certificate of analysis: documented heavy-metal and microbial testing reduces contaminant exposure from feather or wool raw materials.

Therapeutic Protocol

Doses below are cited to their source; other parameters without a citation, such as timing, splitting, cycling, and titration, reflect common practice.

  • Wool keratin, cosmetic dose: 500 mg/day solubilized keratin taken after breakfast, in the hair, nail, and skin trials (Beer 2014) and, as keratin alone, the knee osteoarthritis trial (Beer 2013).
  • Feather hydrolysate, cosmetic dose: 500 or 1,000 mg/day, split between breakfast and dinner, for 90 days (Tursi 2025); no significant difference between doses on most skin measures.
  • Protein-level dose: 0.8 g/kg body weight/day of soluble feather keratin replacing casein during endurance training, studied by the Massey University group (Crum 2018).
  • Commercial combination approach: Life Extension popularized Cynatine HNS combined with collagen peptides, biotin, and silicon (Life Extension label); keratin-alone ingredients such as Kera-Diet represent the competing single-ingredient approach. No head-to-head comparison exists.
  • Time of day: morning after breakfast (Beer 2014) and split with meals (Tursi 2025) have both been used; no evidence favors a specific time.
  • Half-life: no half-life applies; keratin is digested like dietary protein, and plasma amino acids peak about 20 minutes after ingestion (Wauquier 2026), supporting daily intake.
  • Single versus split dosing: both single daily and twice-daily schedules were effective in trials; protein-level doses are typically spread across meals.
  • Genetic polymorphisms: no pharmacogenetic data exist; cystinuria and Wilson’s disease variants bear on product choice because of keratin’s cystine content and the copper in some formulas.
  • Sex: cosmetic trials enrolled only women and the protein trial only men; doses did not differ by sex, and no sex-specific dosing data exist.
  • Age: trials enrolled adults up to 71; no age-specific dosing exists, and older adults using protein-level doses typically count keratin toward total daily protein.
  • Baseline biomarkers: no biomarker predicts response; iron deficiency, thyroid disease, and low protein intake are commonly checked first because they cause shedding and brittle nails independently.
  • Pre-existing conditions: knee osteoarthritis was studied at 500 mg/day (Beer 2013); chronic kidney disease limits protein-level doses under a guideline whose authors gain no revenue from keratin (Ikizler 2020).

Discontinuation & Cycling

  • Lifelong or short-term: trials lasted 4–14 weeks; no data show whether benefits persist after stopping or whether use beyond 14 weeks adds benefit or risk.
  • Withdrawal effects: none reported; keratin is a food protein with no dependence or rebound mechanism.
  • Tapering: not needed; it can be stopped at once, although biotin in combination products bears on the timing of blood tests.
  • Cycling: no evidence supports cycling for efficacy; because hair and nails grow slowly, effects are usually judged after about 3 months before deciding whether to continue.

Sourcing and Quality

  • Source material: Cynatine is processed from New Zealand sheep wool (Beer 2014); Kera-Diet (KeraGLO in the US) is hydrolyzed poultry feather keratin (Tursi 2025).
  • Processing defines the product: peptide-rich wool keratin and free-amino-acid feather hydrolysates differ chemically, so trial results apply only to the tested ingredient and dose. Unprocessed keratin is essentially indigestible (Giteru 2023).
  • Full formula: many “keratin” products add biotin (sometimes 5–10 mg), zinc, copper, collagen, or fish-derived ingredients, which change both effects and risks.
  • Third-party testing: ConsumerLab has not tested keratin products; NSF International or USP seals (independent product-testing marks) on the finished product, plus a certificate of analysis for heavy metals, indicate quality control.
  • Reputable brands: Life Extension’s Hair, Skin & Nails Collagen Plus formula contains Cynatine HNS (Life Extension label); ingredient makers Roxlor (Cynatine) and BCF Life Sciences (Kera-Diet) supply other brands.
  • Dietary restrictions: all keratin supplements are animal-derived and not vegan; the poultry or wool origin matters for people following religious or ethical dietary rules.

Practical Considerations

  • Time to effect: nail and skin changes appeared by day 45 (Tursi 2025), pull-test shedding differed from placebo by day 60 (Beer 2014), and lean-mass change appeared within 4 weeks (Crum 2018).
  • Common pitfalls: assuming any keratin product matches the tested brands; crediting keratin for effects of biotin or zinc; overlooking treatable causes of hair loss; and forgetting to disclose biotin intake before blood tests.
  • Regulatory status: in the US keratin is sold as a dietary supplement, which the FDA does not approve before marketing (FDA dietary supplement Q&A).
  • Cost and funding: keratin supplements are inexpensive and widely available; no insurer covers them, so payer incentives do not shape this evidence, whereas ingredient makers funded or co-authored nearly all human trials.

Interaction with Foundational Habits

  • Sleep: None. No study has measured sleep outcomes with keratin, and no plausible mechanism links it to sleep; evening dosing with dinner was used in one trial without reported sleep effects (Tursi 2025).
  • Nutrition: Indirect. Keratin adds cysteine-rich protein, so its value likely shrinks when dietary protein is ample. In the cycling trial, food protein intake fell during keratin use (Crum 2018); in rats, fat digestibility dropped (Wolber 2016). Protein-level doses count toward daily protein targets.
  • Exercise: Potentiating for lean mass, neutral for performance. Keratin plus endurance training increased leg lean mass more than casein but did not improve power or oxygen uptake (Crum 2018). Resistance training has not been tested; post-workout timing is common practice.
  • Stress management: Indirect. Keratin does not affect cortisol in any study, but stress-triggered telogen effluvium (temporary diffuse shedding after stress or illness) is a common reason for hair formulas; addressing the stressor remains the primary lever for that shedding.

Monitoring Protocol & Defining Success

Baseline testing: typical starting measures are standardized photographs of hair, nails, and face, and a shed-hair count on a set wash day. For hair concerns, a clinician pull test gives an objective starting value. For protein-level doses, eGFR is checked first because kidney disease limits protein intake. For body-composition goals, a baseline DEXA scan is taken on the same machine that will be used later. Typical cosmetic doses of 0.5–1 g/day need no laboratory tests.

Ongoing monitoring: photographs and shed-hair counts are repeated at 6 weeks and 3 months, matching trial timepoints, then every 6–12 months if use continues. eGFR is repeated every 6–12 months for protein-level use, and DEXA after 3 months of training. Biotin-containing formulas are paused at least 3 days before any scheduled blood tests.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
eGFR ≥60 mL/min/1.73 m² (below this is chronic kidney disease stage 3, the threshold for protein restriction in KDOQI 2020) Safety check before protein-level doses Kidney filtering capacity from serum creatinine; KDOQI (Kidney Disease Outcomes Quality Initiative), whose guideline authors gain no revenue from keratin, recommends protein restriction in stages 3–5 (Ikizler 2020); conventional laboratory reference: ≥60 mL/min/1.73 m² (standard reference range); avoid heavy exercise or large meat meals the day before
Hair pull test (hairs extracted) No established target; track change from own baseline Expected to change (main hair outcome) Gentle traction on about 60 hairs at three scalp sites; no washing for 2–3 days beforehand; more than 9 extracted hairs suggested telogen effluvium in the trial protocol (Beer 2014)
DEXA lean mass No established target; track change from own baseline Expected to change with protein-level doses Dual-energy X-ray absorptiometry; same scanner, fasted and similarly hydrated; lean-mass gains were seen within 4 weeks (Crum 2018)

Qualitative markers:

  • Hair shedding: number of hairs lost on a standard wash day.
  • Nail condition: frequency of splitting, peeling, or breakage.
  • Skin feel: dryness, smoothness, and firmness in photographs.
  • Digestive tolerance: bloating or sulfur-smelling flatulence, especially at protein-level doses.
  • Training recovery: perceived recovery and strength when keratin is used as a protein source.

Emerging Research

  • Keratin alone for acute shedding (ISRCTN16660729): placebo-controlled trial of hydrolyzed keratin (KerPep) in adults aged 18–60 with acute telogen effluvium; primary endpoint hair shedding at 3 months. Completed March 2026; no results posted. A positive result would strengthen keratin-alone support for hair shedding; a null result would weaken it.
  • Biotin–collagen–keratin complex (NCT07520019): 40 adults with thinning hair compare 5,000 versus 10,000 mcg biotin in the same complex; registered completion June 2026, still listed active, no results posted. Because both arms contain keratin, neither a positive nor a null result would change conclusions about keratin.
  • Kera-Diet serum bioactivity (NCT06612866): 10 healthy volunteers; registered completion May 2025; results published, showing ex vivo effects (participants’ serum tested on cultured skin cells) (Wauquier 2026), reflected in the antioxidant item.
  • Derm Aid virtual study (NCT04249128): 75 participants in an eight-arm study including collagen-and-keratin products; completed February 2021, no results posted.
  • Independent replication: every human trial was manufacturer-linked; a meta-analysis including Cynatine called for independent research (Alanazi 2026). Independent confirmation could raise grades; failure to replicate would lower them.
  • Keratin with and without vitamins: the hair-nail trial authors proposed testing Cynatine with and without its vitamins (Beer 2014); this could show whether keratin contributes anything beyond biotin and zinc.
  • Muscle and protein quality: the lean-mass signal needs testing against unsupplemented and whey controls, with resistance training and older adults (Crum 2018); a null result would remove the most longevity-relevant benefit.
  • Long-term safety: reviewers call for prolonged human exposure studies of newer extraction methods (Giteru 2023); findings on kidneys, allergy, or contaminants could weaken the low-risk profile.

Conclusion

Solubilized keratin is the structural protein of wool and feathers, processed so the gut can absorb it and sold mainly in hair, skin, and nail supplements. It is unusually rich in a sulfur-containing amino acid the body uses to build keratin and antioxidant defenses.

The human evidence is thin and was funded or co-written almost entirely by the ingredient makers. Given alone, the protein has been linked in small placebo-controlled studies to firmer nails and smoother, more elastic skin, and one small training study suggested extra lean tissue compared with milk protein. Each of these rests on one or two small studies, and a second trial found no nail benefit. Knee arthritis pain eased sooner than with placebo, an advantage gone by two months. Evidence for reduced hair shedding comes mainly from formulas that also contain biotin, zinc, and other B vitamins, so keratin’s own share is uncertain. It did not improve endurance capacity or blood oxygen-carrying measures. Antioxidant effects remain unconfirmed in people, and blood-fat effects rest only on animal work.

Reported side effects are minor: occasional digestive discomfort and sulfur-smelling flatulence at protein-sized amounts. The more practical concerns come from companion ingredients: biotin can distort some blood tests, zinc can reduce absorption of certain antibiotics, and copper-containing formulas are unsuitable for people with inherited copper-storage disease.

For health-focused adults, solubilized keratin is a low-risk cosmetic and protein option whose appearance benefits are plausible but unconfirmed by independent researchers, and whose relevance to longevity remains theoretical.

Top - Benefits - Risks - Protocol